Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 30 May 2025
Accepted: 18 September 2025
First Online: 3 October 2025
Declarations
:
: CPS has received research support from Eli Lilly and Company, Roche, and Genentech; has received speaking fees from Eli Lilly and Company, Eisai, and Roche; and has served as an advisor to Eli Lilly and Company and Eisai. AK, JB, and JH are employees and shareholders of Eli Lilly and Company.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the conception and design of this review, drafted and/or critically revised the work, read and approved the final submitted manuscript, and agreed to be accountable for the work.
